Shareholders of JW (Cayman) Therapeutics (HKG:2126) will meet June 3 to vote on a proposed license agreement between the company and substantial shareholder Juno Therapeutics, a Thursday Hong Kong bourse filing said.
Under the agreement entered into in April, the drugmaker granted Juno Therapeutics a non-exclusive license under the JW sLVV Manufacturing Process solely to develop, commercialize, manufacture, or have manufactured certain products worldwide.
The scope of the agreement encompasses any product involving the use of genetically engineered cells to treat any disease or conditions. Juno Therapeutics or affiliates either own the intellectual property rights of these products or have obtained licenses for them.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.